Selected research
Industry Growth & Trends
Global DNA & RNA Oligonucleotides Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global DNA & RNA Oligonucleotides market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for DNA & RNA Oligonucleotides is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for DNA & RNA Oligonucleotides is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for DNA & RNA Oligonucleotides is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the DNA & RNA Oligonucleotides market include Berry Genomics, BGI, Brooks Life Sciences, Dna Link, Eurofins Scientific, Genotypic Technology, Illumina, LabCorp and Macrogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global DNA & RNA Oligonucleotides market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The DNA & RNA Oligonucleotides market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global DNA & RNA Oligonucleotides market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to DNA & RNA Oligonucleotides.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global DNA & RNA Oligonucleotides market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
DNA & RNA Oligonucleotides Market by Company
Berry Genomics
BGI
Brooks Life Sciences
Dna Link
Eurofins Scientific
Genotypic Technology
Illumina
LabCorp
Macrogen
Natera
Roche
DNA & RNA Oligonucleotides Segment by Type
DNA Oligonucleotides
RNA Oligonucleotides
DNA & RNA Oligonucleotides Segment by Application
Biopharma Companies
Academic & Research Organizations
Hospitals and Clinics
Others
DNA & RNA Oligonucleotides Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DNA & RNA Oligonucleotides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DNA & RNA Oligonucleotides and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DNA & RNA Oligonucleotides.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of DNA & RNA Oligonucleotides companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- DNA Oligonucleotides
- RNA Oligonucleotides
Applications
- Biopharma Companies
- Academic & Research Organizations
- Hospitals and Clinics
- Others
Companies covered
- Berry Genomics
- BGI
- Brooks Life Sciences
- Dna Link
- Eurofins Scientific
- Genotypic Technology
- Illumina
- LabCorp
- Macrogen
- Natera
- Roche
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global DNA & RNA Oligonucleotides Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global DNA & RNA Oligonucleotides Market Size by Region (2021-2032)
- 1.4.1 Global DNA & RNA Oligonucleotides Market Size by Region (2021-2026)
- 1.4.2 Global DNA & RNA Oligonucleotides Market Size by Region (2027-2032)
- 1.5 Key Regions DNA & RNA Oligonucleotides Market Size (2021-2032)
- 1.5.1 North America DNA & RNA Oligonucleotides Market Size Growth Rate (2021-2032)
- 1.5.2 Europe DNA & RNA Oligonucleotides Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific DNA & RNA Oligonucleotides Market Size Growth Rate (2021-2032)
- 1.5.4 South America DNA & RNA Oligonucleotides Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa DNA & RNA Oligonucleotides Market Size Growth Rate (2021-2032)
2 DNA & RNA Oligonucleotides Market by Type
- 2.1 Type Introduction
- 2.1.1 DNA Oligonucleotides
- 2.1.2 RNA Oligonucleotides
- 2.2 Global DNA & RNA Oligonucleotides Market Size by Type
- 2.2.1 Global DNA & RNA Oligonucleotides Market Size Overview by Type (2021-2032)
- 2.2.2 Global DNA & RNA Oligonucleotides Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global DNA & RNA Oligonucleotides Market Size Forecasted by Type (2027-2032)
- 2.3 Global DNA & RNA Oligonucleotides Market Size by Regions
- 2.3.1 North America DNA & RNA Oligonucleotides Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe DNA & RNA Oligonucleotides Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific DNA & RNA Oligonucleotides Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America DNA & RNA Oligonucleotides Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa DNA & RNA Oligonucleotides Market Size Breakdown by Type (2021-2026)
3 DNA & RNA Oligonucleotides Market by Application
- 3.1 Type Introduction
- 3.1.1 Biopharma Companies
- 3.1.2 Academic & Research Organizations
- 3.1.3 Hospitals and Clinics
- 3.1.4 Others
- 3.2 Global DNA & RNA Oligonucleotides Market Size by Application
- 3.2.1 Global DNA & RNA Oligonucleotides Market Size Overview by Application (2021-2032)
- 3.2.2 Global DNA & RNA Oligonucleotides Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global DNA & RNA Oligonucleotides Market Size Forecasted by Application (2027-2032)
- 3.3 Global DNA & RNA Oligonucleotides Market Size by Regions
- 3.3.1 North America DNA & RNA Oligonucleotides Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe DNA & RNA Oligonucleotides Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific DNA & RNA Oligonucleotides Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America DNA & RNA Oligonucleotides Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa DNA & RNA Oligonucleotides Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 DNA & RNA Oligonucleotides Industry Trends
- 4.2 DNA & RNA Oligonucleotides Industry Drivers
- 4.3 DNA & RNA Oligonucleotides Industry Opportunities and Challenges
- 4.4 DNA & RNA Oligonucleotides Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by DNA & RNA Oligonucleotides Revenue (2021-2026)
- 5.2 Global DNA & RNA Oligonucleotides Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global DNA & RNA Oligonucleotides Key Company Headquarters & Area Served
- 5.4 Global DNA & RNA Oligonucleotides Company, Product Type & Application
- 5.5 Global DNA & RNA Oligonucleotides Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global DNA & RNA Oligonucleotides Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 DNA & RNA Oligonucleotides Players Market Share by Revenue in 2025
- 5.6.3 2025 DNA & RNA Oligonucleotides Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Berry Genomics
- 6.1.1 Berry Genomics Company Information
- 6.1.2 Berry Genomics Business Overview
- 6.1.3 Berry Genomics DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Berry Genomics DNA & RNA Oligonucleotides Product Portfolio
- 6.1.5 Berry Genomics Recent Developments
- 6.2 BGI
- 6.2.1 BGI Company Information
- 6.2.2 BGI Business Overview
- 6.2.3 BGI DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 BGI DNA & RNA Oligonucleotides Product Portfolio
- 6.2.5 BGI Recent Developments
- 6.3 Brooks Life Sciences
- 6.3.1 Brooks Life Sciences Company Information
- 6.3.2 Brooks Life Sciences Business Overview
- 6.3.3 Brooks Life Sciences DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Brooks Life Sciences DNA & RNA Oligonucleotides Product Portfolio
- 6.3.5 Brooks Life Sciences Recent Developments
- 6.4 Dna Link
- 6.4.1 Dna Link Company Information
- 6.4.2 Dna Link Business Overview
- 6.4.3 Dna Link DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Dna Link DNA & RNA Oligonucleotides Product Portfolio
- 6.4.5 Dna Link Recent Developments
- 6.5 Eurofins Scientific
- 6.5.1 Eurofins Scientific Company Information
- 6.5.2 Eurofins Scientific Business Overview
- 6.5.3 Eurofins Scientific DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Eurofins Scientific DNA & RNA Oligonucleotides Product Portfolio
- 6.5.5 Eurofins Scientific Recent Developments
- 6.6 Genotypic Technology
- 6.6.1 Genotypic Technology Company Information
- 6.6.2 Genotypic Technology Business Overview
- 6.6.3 Genotypic Technology DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Genotypic Technology DNA & RNA Oligonucleotides Product Portfolio
- 6.6.5 Genotypic Technology Recent Developments
- 6.7 Illumina
- 6.7.1 Illumina Company Information
- 6.7.2 Illumina Business Overview
- 6.7.3 Illumina DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Illumina DNA & RNA Oligonucleotides Product Portfolio
- 6.7.5 Illumina Recent Developments
- 6.8 LabCorp
- 6.8.1 LabCorp Company Information
- 6.8.2 LabCorp Business Overview
- 6.8.3 LabCorp DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 LabCorp DNA & RNA Oligonucleotides Product Portfolio
- 6.8.5 LabCorp Recent Developments
- 6.9 Macrogen
- 6.9.1 Macrogen Company Information
- 6.9.2 Macrogen Business Overview
- 6.9.3 Macrogen DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Macrogen DNA & RNA Oligonucleotides Product Portfolio
- 6.9.5 Macrogen Recent Developments
- 6.10 Natera
- 6.10.1 Natera Company Information
- 6.10.2 Natera Business Overview
- 6.10.3 Natera DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Natera DNA & RNA Oligonucleotides Product Portfolio
- 6.10.5 Natera Recent Developments
- 6.11 Roche
- 6.11.1 Roche Company Information
- 6.11.2 Roche Business Overview
- 6.11.3 Roche DNA & RNA Oligonucleotides Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Roche DNA & RNA Oligonucleotides Product Portfolio
- 6.11.5 Roche Recent Developments
7 North America
- 7.1 North America DNA & RNA Oligonucleotides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America DNA & RNA Oligonucleotides Market Size by Country (2021-2026)
- 7.3 North America DNA & RNA Oligonucleotides Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe DNA & RNA Oligonucleotides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe DNA & RNA Oligonucleotides Market Size by Country (2021-2026)
- 8.3 Europe DNA & RNA Oligonucleotides Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific DNA & RNA Oligonucleotides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific DNA & RNA Oligonucleotides Market Size by Country (2021-2026)
- 9.3 Asia-Pacific DNA & RNA Oligonucleotides Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America DNA & RNA Oligonucleotides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America DNA & RNA Oligonucleotides Market Size by Country (2021-2026)
- 10.3 South America DNA & RNA Oligonucleotides Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa DNA & RNA Oligonucleotides Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa DNA & RNA Oligonucleotides Market Size by Country (2021-2026)
- 11.3 Middle East & Africa DNA & RNA Oligonucleotides Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst